USFDA approves Zydus' USP, 1% clindamycin phosphate gel for treating acne

21 Sep 2023 , 12:23 PM

On Wednesday, September 20, the pharmaceutical company Zydus Lifesciences Ltd. announced that it has attained a critical milestone by receiving final approval from the US Food and Drug Administration (USFDA) for its Clindamycin Phosphate Gel USP, 1%.

One of the most important treatments for acne, clindamycin phosphate gel USP, 1% significantly lowers the number of acne lesions. According to a stock exchange filing, the drug makes use of the antibiotic clindamycin, which is effective at preventing the growth of germs that cause acne.

According to the business, Zydus Lifesciences will produce this crucial pharmaceutical product at its cutting-edge topical manufacturing facility in Changodar, Ahmedabad.

According to information from IQVIA MAT as of July 2023, clindamycin phosphate gel USP, 1% has recently seen extraordinary performance in the American pharmaceutical market, with yearly sales approaching $37 million.

Zydus Lifesciences Ltd. has steadily increased its market share in the pharmaceutical industry and has accumulated a noteworthy portfolio of 381 approvals. As of June 30, 2023, the company had submitted over 444 abbreviated new drug applications (ANDAs) since the filing procedure began in FY 2003-04.

For feedback and suggestions, write to us at [e-mail]